Valuation: Fate Therapeutics, Inc.

Market Cap 21Cr 19Cr 18Cr 16Cr 30Cr 2.04TCr 31Cr 212.41Cr 83Cr 1.06TCr 80Cr 79Cr 3.39TCr P/E 2026 *
-1.68x
P/E 2027 * -1.73x
Enterprise Value 21Cr 19Cr 18Cr 16Cr 30Cr 2.04TCr 31Cr 212.41Cr 83Cr 1.06TCr 80Cr 79Cr 3.39TCr EV / Sales 2026 *
38x
EV / Sales 2027 * 45x
Free-Float
98.94%
Yield 2026 *
-
Yield 2027 * -
1 day-7.01%
1 week-17.89%
Current month-24.47%
1 month-26.64%
3 months-34.43%
6 months+30.66%
Current year+82.17%
1 week 1.78
Extreme 1.78
2.18
1 month 1.78
Extreme 1.78
2.63
Current year 0.97
Extreme 0.97
3.23
1 year 0.95
Extreme 0.95
3.23
3 years 0.66
Extreme 0.66105
8.83
5 years 0.66
Extreme 0.66105
66.56
10 years 0.66
Extreme 0.66105
121.16
Manager TitleAgeSince
Chief Executive Officer 49 01/01/2025
Director of Finance/CFO 47 20/10/2025
Chief Operating Officer - 01/07/2021
Director TitleAgeSince
Chairman 78 01/12/2011
Director/Board Member 70 17/03/2014
Director/Board Member 47 31/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
04/08/26 Sell

Chief Executive Officer

-43,947 0.0377%
04/08/26 Sell

Compliance Officer

-38,800 0.0333%
12/06/26
Redmile Group LLC
FreeCompany 87,900 0.0754%
Change 5-day change 1-year change 3-year change Capi.($)
-7.01%-17.89%+16.23%+1.13% 21Cr
-6.60%-8.56%+42.79%+64.16% 6.5TCr
-4.09%-0.11%+2.31%+54.81% 5.12TCr
+0.03%+5.56%+10.18%+41.75% 5.12TCr
-1.53%+2.70%+29.72%+34.13% 4.39TCr
-1.34%+4.12%+16.05%+112.18% 4.2TCr
-5.97%-6.22%+258.21%+421.57% 3.81TCr
+6.53%+8.02%+15.74%+53.94% 3.32TCr
-0.90%-10.49%+31.48%-1.63% 2.52TCr
-2.76%-9.54%-16.53%-9.55% 2.2TCr
Average -2.36%-3.29%+40.62%+77.25% 3.72TCr
Weighted average by Cap. -2.30%-1.22%+43.55%+88.53%

Financials

2026 *2027 *
Net sales 56.49L 50.22L 46.54L 42.35L 79.91L 54Cr 81.19L 5.59Cr 2.19Cr 28Cr 2.12Cr 2.08Cr 89Cr 47.67L 42.37L 39.27L 35.73L 67.42L 45Cr 68.5L 4.72Cr 1.85Cr 24Cr 1.79Cr 1.75Cr 75Cr
Net income -13Cr -11Cr -11Cr -9.66Cr -18Cr -1.22TCr -19Cr -127.58Cr -50Cr -638.03Cr -48Cr -47Cr -2.03TCr -15Cr -13Cr -12Cr -11Cr -21Cr -1.39TCr -21Cr -144.61Cr -57Cr -723.2Cr -55Cr -54Cr -2.31TCr
Net Debt - -
Projected Income Statement - Annual - Fate Therapeutics, Inc.
Logo Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.
Employees
161
Date Price Change Volume
16/26/16 $1.790 -7.01% 13,84,493
15/26/15 $1.925 -0.77% 11,57,826
14/26/14 $1.940 -3.00% 16,74,322
13/26/13 $2.000 -6.10% 9,53,482
12/26/12 $2.130 -2.29% 6,16,845
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Fate Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
1.790USD
Average target price
5.744USD
Spread / Average Target
+220.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Fate Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. FATE Stock